Recent webinar featuring Prime Therapeutics experts shares some of the latest breakthrough therapies — including ADCs, BiTes and CAR-T treatments — and regulatory changes and market shifts that are...

The SIU promotes safety to prevent fraud, waste and abuse schemes

Parikh, director of medical pharmacy strategy at Prime/MRx, shares the latest on interchangeable biosimilars

Clinical Solutions VP (Remote) Looking for your next career move and want to help Prime Therapeutics (Prime) put more care in health care? Check out the Prime Careers Spotlight, a monthly roundup...

Dinesh Kandanchatha joined the organization July 1.

Prime Therapeutics/Magellan Rx Management's signature event featured the hottest topics in specialty drug management and more

As the efficacy and cost of these therapies become clear, so is the need for thoughtful managed care strategies, according to Prime Therapeutics thought leaders

New report highlights value-based contract solution and analysis of top 10 drug classes impacting Medicaid pharmacy net trend

Insights from Academy of Managed Care Pharmacy (AMCP) Nexus 2023

Prime Therapeutics offers first-of-its-kind digital utilization management solution that pairs biomarker testing with targeted therapy drug selection

Prime works to simplify medication management and support patients with migraine, making migraine treatment less of a pain point

Lead author David Eckwright shares more about the study “Real-World Extended Dosing Assessment for Eye(s) new to Faricimab-svoa Therapy.”

Cover image for Drug Approvals Monthly Update: September 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty...

Cover image for Drug Approvals Monthly Update: August 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty...

Cover AMCP Prime Therapeutics /amcp-nexus-2024-research-posters 10 research posters presented by Prime at AMCP Nexus 2024 covers topics like GLP-1 obesity research, health equity initiatives, and...

Cover image for 8 research posters presented by Prime at the 2024 AMCP Annual Meeting 2024 AMCP Annual Meeting Prime Therapeutics /2024-amcp-annual-meeting-research-posters 8 research posters...

This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process.

This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process.

Drug Approvals Quarterly Update: July 2024 This wrap-up provides a review of newly approved drugs, recent drug launches, new indications and news of note on drugs in the approval process. Prime...

Constant communication across the supply chain limits disruption when a drug is unavailable

A strategic deep dive into the latest trend report from Prime Therapeutics reveals how oncology spend is evolving across benefits and what it means for cancer care management

Cover image for FDA Decisions Expected_February 2025 Drug pipeline for February 2025 Prime Therapeutics /fda-decisions-expected-february-2025 About Prime Therapeutics Prime Therapeutics logo Prime...

Prime’s Special Investigations Unit is specially trained to protect patients and providers throughout the health care continuum

Event features Pat Gleason, AVP, health outcomes at Prime Therapeutics

Cover image for FDA Decisions Expected: November 2024 Drug pipeline for November 2024 Prime Therapeutics /fda-decisions-expected-november-2024 Prime Therapeutics’ FDA Decisions Expected outlines...

Jessica Johnson, clinical consultant at Prime Therapeutics, shares some ways to avoid common fraud schemes

References 1. U.S. Food and Drug Administration. Application number 761381: Opdivo Qvantig (nivolumab and hyaluronidase-nvhy). Drugs@FDA. Accessed February 6, 2026....

Home Other Navigation Pharmacy + Providers Pharmacy Credentialing Important information Updated Insurance Coverage Information To submit a renewal, submit your updated certificate of insurance to...

Commercial information Your Choices Regarding Your Information You may have the following rights with respect to your personal information, subject to applicable exceptions: Right to access. You...

These new solutions reflect Prime's distinctive conflict-free approach to the prescription drug supply chain model.

Pharmacy Friends In the latest episode of the “Pharmacy Friends” podcast, learn the latest insights on legislative trends, cutting-edge drug therapies and more from the 22nd annual event Alex Cook...

Home Newsroom Custom Content Publications High Cost Therapy Profile 2024-2025 High-Cost Therapy Profile: September 2024 Oncology/ cellular therapy Obecabtagene autoleucel Intravenous (IV) Autolus...

A female-presenting person speaks at a legislative building, wearing a green blazer and glasses. George Van Antwerp breaks down how Prime is poised to drive affordability in drug pricing Alex Cook...

Upgrade provides streamlined patient support and enhanced digital engagement for data-driven, holistic care

New Biosimilars First Generic Drug Launches Oct. 25, 2024 - sulopenem etzadroxil and probenecid (Orlynvah) The FDA has approved Iterum’s Orlynvah for the treatment of uncomplicated urinary tract...

FDA approved BiTEs: Brand name Generic name Route Target Indication First FDA indication approval date Blincyto Blinatumomab IV anti-CD19 / anti-CD3 Acute lymphocytic leukemia 12/3/2014 Columvi...

Based on the clinical trial, there are certain expectations for how long patients can anticipate seeing the benefits of treatment. The median duration of response was 11.6 months (95% CI, 4.4 to...

This decision to remove REMS comes one year after the FDA loosened REMS requirements and removed the site mandate for CAR T educational and training materials because they deemed the product label...

Scientists have made remarkable progress in understanding the thousands of genes inside our cells and the link they may have to cancer. Researchers continue to discover patient-specific...

Successfully complete new hire orientation Complete training to gain competency in SA, RxClaims and MSA Toolbox Attend Prime intern activities, such as volunteer opportunities and intern lunch and...

Therapy options Keytruda (Pembrolizumab) Adstiladrin (nadofaragene firadenovec-vncg) Anktiva (nogapendekin alfa inbakicept-pmln) + BCG Study KEYNOTE-057, phase 2, open label; 5-year follow-up;...

Cover image for Prime Therapeutics prioritizes patient-centered care, stays ahead of oncology trends Prime simplifies the cancer care pathway through innovative solutions that help manage complex...

References National Cancer Institute. (2020, October 26). Radiopharmaceuticals: radiation therapy enters the molecular age....

Medication insights: teprotumumab-trbw (Tepezza) The U.S. Food and Drug Administration (FDA) first approved teprotumumab-trbw (Tepezza) in January 2020 for the treatment of thyroid eye disease...

Effective: January 2021 Terms of use IF YOU ARE EXPERIENCING A MEDICAL EMERGENCY, DIAL 911 AND/OR SEEK IMMEDIATE ATTENTION FROM A HEALTH CARE PROVIDER. THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE....

Event features Prime's Health Outcomes team

Forbes

Zabrina Watkins Radical welcomeness “At Prime we’re committed to creating an open, inclusive culture that’s purpose-oriented and focused on providing meaningful work for our employees. To do this,...

Oncology Insights On May 16, the U.S. Food and Drug Administration (FDA) granted accelerated approval to intravenous Imdelltra™ (tarlatamab) for the treatment of adults with relapsed/refractory...

Sept. 27, 2024 - ustekinumab-aauz (Otulfi) Fresenius Kabi has received FDA approval for Otulfi as a biosimilar to ustekinumab (Stelara). This human interleukin (IL)-12 and IL-23 antagonist is...

Managed Markets Insight & Technology (MMIT)

Home Other Navigation Pharmacy + Providers Commercial Formularies PrimeChoice Accord™ Formulary PrimeChoice Accord™ Formulary Updates NetResults™ A-Series Prescription Drug Guide NetResults™...

Tennessee In accordance with Texas Senate Bill 1236, Prime Therapeutics provides Texas-based pharmacies with secure online access to their pharmacy benefit network contracts that were executed on...

March 7, 2025 – rivaroxaban 2.5 mg tablet (Xarelto) Lupin launched a generic to Janssen’s Xarelto Factor Xa inhibitor indicated (1) to reduce the risk of major cardiovascular events in patients...

New or expanded indications March 12, 2025 – fluocinolone acetonide intravitreal implant (Iluvien) Alimera; corticosteroid; supplemental NDA (sNDA) approved for consolidation of labeling of...

This form is specifically used to request a check reissue. For remittance requests, please use the following link: Pharmacy remittance request - Prime Therapeutics LLC. Prime Therapeutics cannot...

Disclaimer THIS WEBSITE IS AN OPTIONAL RESOURCE FOR HEALTH CARE PROVIDERS ONLY. IF YOU ARE NOT A HEALTH CARE PROVIDER OR AUTHORIZED PROFESSIONAL USER, YOU ARE NOT TO USE THIS SITE AT ALL AND ARE...

December 2024 December 2023 June 2024 December 2021 Pharmacy newsletter from Prime Therapeutics that provides information and updates about Prime services. June 2022 Home Other Navigation Pharmacy...

publications Fall 2024 Prime Therapeutics Report October 21, 2024 Debuting a new name and design, the 41st edition of our managed care report still offers the same in-depth industry articles on...

New approach aligns with long-standing biosimilar strategy